Science news

Duke Energy crews assess damage, restore power for thousands of customers across Carolinas

World Reviewer Staff

Read the latest science news headlines and see what’s new in science. WeeklyReviewer brings you top science headlines from leading industry news.

Science is a rapidly changing and growing platform. Make sure you are always up to date on what’s new in science!

Duke Energy Florida aims to restore 90% of customers in its service territory by Sunday

Most customers to be restored by midnight SundayMore than 861,000 customers have been restored thus farRestoration times have been posted for all Duke Energy...

Duke Energy crews continue to focus on Carolinas' hardest-hit regions; nearly 750,000 customers restored in past 24 hours

Company continues to move additional repair crews into areas with outagesMore than 95% of customers will be restored by tomorrow nightEstimated restoration times will...

Government of Canada providing assistance to Atlantic Canada with recovery from Hurricane Fiona

OTTAWA, ON, Oct. 1, 2022 /CNW/ - Hurricane Fiona has caused significant damage across Atlantic Canada and Eastern Quebec, and the Government of Canada...

Announcing Director of White House Office of National Drug Control Policy as Guest Speaker at Faces & Voices of Recovery's Recovery Leadership Summit

Dr. Gupta joins Johann Hari, Chacku Mathai, and Maia Szalavitz as speakers at this year's conference. ST. PAUL, Minn., Oct. 1, 2022 /PRNewswire-PRWeb/ -- Faces...

Uniform Advantage Donates $20,000 to the Breast Cancer Research Foundation

Uniform Advantage, a multi-channel retailer of medical uniforms for medical and hospitality industries, is proud to continue its partnership with the Breast Cancer Research...

Tanger Continues Support of Breast Cancer Research and Programs, Elevates Commitment with Tanger Pink 2022

Longstanding giving program furthers $18.5 million investment in national breast cancer advocacy work and continues support of community nonprofit organizations GREENSBORO, N.C., Sept. 30, 2022...

FDA Approves Taiho's LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

LYTGOBI (pronounced "light-GOH-bee") delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the...